A reduced dose of obinutuzumab, an immunosuppressant approved for certain blood cancers, safely helped most adults with ANCA-associated vasculitis (AAV) achieve sustained disease remission, while reducing their need for standard glucocorticoids. That’s according to a single-center study in China involving 12 adults with hard-to-treat AAV and four adults with…
Long-term treatment with Nucala (mepolizumab) is safe and effective in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV), according to a meta-analysis of eight studies. After nearly two years of treatment, more than half of EGPA patients achieved remission, meaning they had…
Induction therapy with cyclophosphamide and rituximab allows for early discontinuation, without compromising efficacy, of an oral-only glucocorticoid regimen in people with severe ANCA-associated vasculitis (AAV), a study found. Patients on oral glucocorticoids for up to three months showed comparable remission and relapse rates, but tended to have fewer infections…
Older age and higher glucocorticoid exposure are significantly associated with a higher risk of death due to infections among people with ANCA-associated vasculitis (AAV), a study showed. Patients older than 65 were more likely to die from complications of life-threatening infections, which can result from using immunosuppressive therapies to…
Get regular updates to your inbox.
